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Heart failure (HF) and cancer are becoming increasingly
prevalent as our population ages. Both conditions are asso-
ciated with signiﬁcant mortality and morbidity. Although
the increased risk of incident HF in patients with cancer
receiving chemotherapy has been well documented (1), little
is currently known about the risk of incident cancer in
patients with HF. In this issue of the Journal, Hasin et al. (2)
explore this association, with interesting results. The inves-
tigators compared patients with incident HF to age-, sex-,
and date-matched community controls without HF (961
pairs, 1979 to 2002) in Olmsted County, Minnesota. They
found that the prevalence of prior cancer was similar in
newly diagnosed HF patients compared with controls. They
further evaluated the cohort without any history of cancer at
index (596 pairs) for the development of incident cancer.See page 881Over 9,203 person-years of follow-up and a mean follow-up
of 7.7 years, patients with HF were found to have a 68%
higher risk of being diagnosed with cancer compared with
controls, after adjusting for body mass index, smoking, and
comorbidities (hazard ratio [HR]: 1.68; 95% conﬁdence
interval [CI]: 1.13 to 2.5). Patients with HF that were
diagnosed with cancer also had a 56% higher risk of death
compared with HF patients without cancer (HR: 1.56; 95%
CI: 1.22 to 1.99) compared with a 93% increased mortality
risk in non-HF controls diagnosed with cancer compared
with controls without cancer (HR: 1.93; 95%CI: 1.51 to 2.46,
p ¼ 0.18 for interaction between HF patients and controls).
On the basis of these ﬁndings, the authors emphasized the
importance of cancer surveillance in patients with HF.*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
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paper to disclose.The study addresses a novel question that may have public
health implications. Noncardiac comorbidities in patients
with HF are being increasingly recognized as having a
signiﬁcant impact on mortality and hospitalizations in HF
patients, with the effect being even more pronounced in
patients with HF and preserved ejection fraction (3). The
study by Hasin et al. (2) addresses the comorbidity of cancer
in patients with HF. A signiﬁcant strength of the investi-
gation is the comprehensive database utilized. Olmstead
County, Minnesota, is isolated from other urban centers,
and medical records from all providers are indexed and
accessible through the Rochester Epidemiology Project, thus
providing an ideal setting for epidemiological research.
The ﬁrst ﬁnding for discussion is that the risk of cancer
may be increased in individuals with HF compared with
non-HF controls. Before we conclude that HF itself causes
an increased risk for cancer, several alternative explanations
need to be considered. Studies on cancer epidemiology are
especially prone to lead-time bias, which is the amount of
time by which the diagnosis of an asymptomatic or less
advanced cancer has been advanced by screening (4). In the
current study, no data are available to compare healthcare
utilization byHF cases and controls. However, on the basis of
the fact that HF patients have more comorbidities and are
almost certainly sicker than non-HF controls, it is reasonable
to assume that they had more frequent encounters with their
primary care physicians, as well as with specialists in both
the inpatient and outpatient settings. This may have con-
tributed to more frequent screening tests for cancer, as well
for other medical testing, compared with non-HF controls,
which may have led to earlier diagnoses of cancer. This effect
of lead-time bias is substantiated by the Kaplan-Meier curves
for the cumulative incidence of cancer in HF patients versus
controls over the entire study period (Fig. 1 in Hasin et al.
[2]). The increased hazard of diagnosis of cancer in HF
patients compared with controls did not appear to be constant
over time. The curve for the HF patients diverges from that
of controls (with a higher risk of cancer in HF patients),
beginning at approximately 2 years after the diagnosis of
HF, with the greatest divergence atw4 years, followed by the
curves coming together at w7 years, and later crossing over
such that the cumulative incidence of cancer in patients with
HF appears to fall below that of controls. This suggests that
an earlier diagnosis of cancer may have occurred in HF
patients. In addition, because the development of cancer is
usually a slow process, it would be unlikely that HF itself
would be the causal factor for the relatively early increase of
cancer.
Furthermore, some of the risk factors for developing
cancer and cardiovascular disorders, including HF, are
similar, such as cigarette smoking. Although the analyses
show that the risk of cancer is independent of a history of
smoking, a dose-response effect of the duration and amount
of smoking (5) would not be accounted for in this analysis,
as would not other unmeasured factors. For example,
patients with HF also have more cardiac and noncardiac
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888comorbidities that could have led to greater radiation expo-
sure from medical imaging, even before the development of
HF, possibly contributing to an increased risk of cancer (6).
Interestingly, a study utilizing the ARIC (Atherosclerosis
Risk in Communities) cohort had suggested that adherence
to heart-healthy behaviors at baseline is associated with
a lower incidence of cancer long term (7), again supporting
a lower incidence of cancer in patients with a lesser risk of
cardiovascular disease. The study by Hasin et al. (2) also
lacked data on medications. Although medications that
are used in HF, as well as in pre-existing cardiovascular
comorbidities, namely, angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers, and calcium channel
blockers, have been implicated for potentially carcinogenic
effects in some experimental and observational studies, there
is a lack of convincing evidence that any of these medications,
in the current doses and durations tested, lead to an increased
risk of cancer (8). Hasin et al. (2) also observed a trend
toward a higher risk of cancer in patients with incident HF in
the second half of the study period (1991 to 2002) compared
with the earlier half (1979 to 1990). Although the authors
suggest that this may parallel the increased use over time of
HF medications such as angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers, it is also
possible that these observations are related to increased
diagnoses of cancer due to more aggressive screening or
medical testing, as well as a possible increase in cancer over
time due to exposure to radiation from increased medical
imaging in patients with pre-existing cardiac and noncardiac
comorbidities (6).
The second important ﬁnding of the study by Hasin et al.
(2) is that the diagnosis of cancer in HF patients was asso-
ciated with increased mortality compared with HF patients
without cancer. This suggests that the comorbidity of cancer
itself may independently contribute to increased mortality in
HF patients, and it is possible that adequate surveillance and
treatment of cancers in this population of patients may have
a beneﬁcial effect on outcomes. However, because data
regarding the treatment of the cancers once they are diag-
nosed, or the cause of the increased mortality, that is, whether
it is cancer related, are not available in the current study,
future studies are needed to examine these issues. Concor-
dant with ﬁndings of a prior study (3), the prognostic impact
of cancer on mortality appeared similar in HF patients withpreserved versus reduced ejection fraction in the subgroup of
patients for whom ejection fraction data were available.
In summary, these ﬁndings of an association of incident
cancer in patients with HF, although novel, should be
interpreted with caution. Further studies are needed to
corroborate these ﬁndings and to answer several important
questions raised by this study. Temporal trends in the
incidence of cancer in patients with HF should be investi-
gated, as should the effect of cancer surveillance on the
diagnosis of cancer, as well as the impact of cancer treatment
on mortality in patients with HF. Lastly, if it is conﬁrmed
that HF is indeed associated with an increased risk of cancer,
the role of various factors, including medications, dietary
habits, radiation exposure, telomere shortening (9,10), and
inﬂammation, will need to be investigated.
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